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ABSTRACT
Objectives: To analyse the effect of biological agents
(BAs) in terms of achieving inactive disease (ID) or
clinical remission (CR) in patients with systemic
juvenile idiopathic arthritis (SJIA), to describe effects
of switching or discontinuing a BA and to assess the
proportion of patients able to maintain ID or CR off
steroids and after withdrawing BA therapy.
Methods: Retrospective study in a French paediatric
rheumatology reference centre using the CEMARA
(CEntre des MAladies RAres) register.
Results: Seventy-seven patients were included with a
cumulative follow-up of 245.5 patient-years (median
1.1, range 0.5–8.0). On a first BA, ID was achieved in
37 patients, including 1 patient out of 12 patients on
etanercept, 26 patients out of 51 on anakinra and 7 out
of 10 on canakinumab. One patient on abatacept and
two patients on tocilizumab also achieved ID.
Switching of BA was common. The switch to a second
(n=34), third (n=18) or fourth (n=4) BA resulted in ID
in a further 13 patients, either on canakinumab (n=6)
or tocilizumab (n=7). At last follow-up, 40 patients
were in CR (27 patients off steroids, 5 patients having
never received steroid treatment), either on (n=29) or
off (n=11) BA.
Conclusions: In this series of patients with SJIA,
interleukin-1 inhibitors were associated with a higher
proportion of ID than tumour necrosis factor inhibitors
when used as first BA. Switching allowed some
patients to achieve ID when treated with canakinumab
or tocilizumab. CR was eventually achieved in more
than half of the patients.
INTRODUCTION
Systemic-onset juvenile idiopathic arthritis
(SJIA) is characterised by spiking fever, evanes-
cent rash, hepatosplenomegaly, serositis,
lymphadenopathy and arthritis. According to
the International League Against Rheumatism
(ILAR) criteria, it has been classified as a
subtype of juvenile idiopathic arthritis.1
However, it presents major differences in com-
parison to other subtypes. Key players of the
innate immunity system are involved in its
pathophysiology, supporting that SJIA is an
autoinflammatory syndrome.2 3
Several biological agents (BAs) have
become available for the treatment of SJIA
over the last decade. The first available and
studied BA in JIA with polyarticular course
was etanercept, a tumour necrosis factor
(TNF)–α receptor antagonist. Several
reports showed a resounding efficacy in
non-systemic JIA, but less consistent effect
in SJIA.4 5
Key messages
What is already known on this subject?
▸ Achievement of inactive disease and clinical
remission (CR) has become a realistic goal for
the treatment of systemic juvenile idiopathic
arthritis.
What does this study add?
▸ Introducing an IL-1 or an IL-6 inhibitor as a first
biologic treatment dramatically increases the
chances of SJIA patients to ever achieve CR, as
compaired to TNF-alpha inhibitors, even if some
patients may achieve CR on canakinumab or
tocilizumab as second or third line biologic
agents.
How might this impact on clinical practice?
▸ In biologic-naive SJIA patients, any IL-1 or an
IL-6 inhibitor may be recommended in a treat-
to-target approach aiming to achieve inactive
disease within a few months; in non-biologic
naive SJIA patients, canakinumab and tocilizu-
mab seem the best options to try and obtain
complete remission.
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Anti-interleukin (IL)-1 and IL-6 therapies have proven
efficacy in clinical trials. Anakinra, the first IL-1 receptor
antagonist, was shown to be effective in SJIA, with evi-
dence of dramatic responses in subgroups of patients
with SJIA.2 6–11 Canakinumab, an anti-IL-1 antibody, and
tocilizumab, an anti-IL-6 receptor antibody, demon-
strated efficacy in SJIA treatment.12 13 Another anti-IL-1
fusion protein, rilonacept, was evaluated in a phase III
trial.14
However, the choice of a BA may be difficult.
Prescription strategies have to take into account
several factors, including the heterogeneity of the
disease course, the availability of BAs and treatment
guidelines with change over time15 16 or national mar-
keting authorisation restrictions. Data from observa-
tional studies, in this situation, provide important
information for the clinician’s decision on starting a
specific BA or switching to another in case of lack of
effectiveness, loss of response or adverse events.
We therefore conducted a retrospective study addres-
sing drug survival, achievement of inactive disease and
reason for switching of BA in SJIA.
PATIENTS AND METHODS
Study design
This was a retrospective study in Necker Enfants-Malades
Hospital, Paris, France, the French reference centre for
rare paediatric rheumatological and inflammatory dis-
eases (CERHUMIP); the study used the CEMARA
(CEntre des MAladies RAres) register, a nationwide
information system for rare diseases.17 The CEMARA
register includes all patients with rare diseases. The data
that are entered represent core information allowing the
identification of the patient, details of medical history,
diagnosis and treatment. After extraction of CEMARA
data, the medical records were fully reviewed. The
CEMARA system benefits from an agreement with the
French National Committee on Informatics and Liberty
(CNIL). According to the French legislation, patients
and parents were informed but no informed consent
form was required for a retrospective analysis.
Patients and treatment
For this study, we identified all patients with a diagnosis
of SJIA based on ILAR criteria who started their first BA
therapy between 1 January 2005 and 30 June 2012.
Patients having been treated with BA before the study
period were excluded. Follow-up of at least 6 months
after BA treatment initiation had to be accomplished in
our centre. The last follow-up registered was on 31
December 2012. The choice of a specific BA treatment
was not restricted in our centre.
Clinical assessment
Baseline patient characteristics included gender, age at
first symptoms and age at diagnosis. Evaluation of medi-
cations included previous and concomitant treatments,
including changes of corticosteroid dosage under BA
treatment.
Clinical evaluation was assessed by the following vari-
ables: active joint count, limited joint count, morning
stiffness, fever, rash, hepatosplenomegaly, generalised
lymphadenopathy, serositis, history of macrophage acti-
vation syndrome and other comorbidity. Laboratory
evaluation included complete blood count, erythrocyte
sedimentation rate, C reactive protein and ferritin (if
available).
Clinical evaluations of patients were recorded at the
start of a new BA, in a time window of 2–5 months after
starting a new BA and at last assessment under BA
therapy, which could be either at last follow-up or at last
assessment before switching to another BA. Drug sur-
vival was assessed at month 3, month 12, month 24 and
at last follow-up, respectively.
Inactive disease required the absence of systemic symp-
toms, active joints and morning stiffness, with a physi-
cian’s assessment that did not exceed 10/100 on the
physician visual analogue scale (VAS), as proposed by
Wallace et al.18 Owing to the retrospective setting, child-
hood health assessment questionnaire (CHAQ) and
parent/patient assessment of disease activity were not
included as supplementary criteria. Achievement of clin-
ical remission on treatment was defined as inactive
disease for >6 months under DMARD, steroids or BA
therapy. Remission off treatment was defined as
>12 months remission after withdrawing any disease-
targeting medication.19
Follow-up, switch of BA and long-term outcome
We classified reasons for switching to a second, third or
fourth BA into the following categories: adverse events,
ineffectiveness, loss of response, convenience of use and
patient’s wish. Follow-up time under a BA was calculated
from start of BA treatment until a switch to another BA
treatment, the last follow-up visit or 31 December 2012,
whichever occurred first.
Long-term outcome was evaluated with the following
items: loss of articular function, short stature (defined as
<2 SDs below the 50th centile), growth hormone treat-
ment and disease-related surgery.
Safety
Safety was assessed by recording all serious adverse
events (SAEs), including medical events of special inter-
est (severe infection, malignancy or organ dysfunction).
Adverse events in immediate relation to a drug adminis-
tration were recorded separately with differentiation into
allergic reaction, infusion reaction or other.
Data analysis
Descriptive statistical analysis was reported as absolute
frequencies. Mean values were given with the SD,
median values were given with the range. One-way ana-
lysis of variance was used for comparison of baseline
characteristics at start of first biological therapy. Fisher’s
2 Woerner A, et al. RMD Open 2015;1:e000036. doi:10.1136/rmdopen-2014-000036
RMD Open
group.bmj.com on August 25, 2015 - Published by http://rmdopen.bmj.com/Downloaded from 
exact test was used to compare achievement of inactive
disease. To describe differences in drug discontinuation,
a log-rank test based on Kaplan-Meier survival was per-
formed. p Values less than 0.05 were considered statistic-
ally significant with a two-sided test performed.
Statistical analysis was performed with SPSS Statistical
software, V.22 (IBM, USA).
RESULTS
Patients and first-line BA therapy
Out of 236 patients included in CEMARA with a diagno-
sis of SJIA, 77 were included (figure 1) with a cumulative
follow-up duration on BA of 245.5 patient-years.
Patients’ characteristics at start of first BA therapy are
described in table 1. Full disease activity and laboratory
parameters were available for 66 patients.
The first BA was anakinra in 51 patients, etanercept in
12, canakinumab in 10, tocilizumab in 2, and adalimu-
mab and abatacept in 1 patient each. Median follow-up
duration on BA was 33.8 months (range 1.8–97.9) for
the patients who did not experience a switch of BA; for
switchers, median follow-up duration on BA was
6.7 months (range 0.5–55.0) under the first BA,
12.0 months (range 0.5–73.6) under the second and
10.6 months (range 2.0–56.2) under the third BA.
Effectiveness of first-line BA therapy and drug survival
Inactive disease was achieved and maintained at last
follow-up in 37 patients (48.1%) without changing BA
therapy. This was observed in 33 out of 61 patients on
anti-IL-1 treatment, the 2 patients on tocilizumab and 1
patient on abatacept, but only in 1 of the 13 patients
who received anti-TNF as first-line BA therapy.
Kaplan-Meier estimates of first BA continuation until
discontinuation due to ineffectiveness, adverse events,
loss of response, convenience of use and patient’s wish,
showed significant differences in favour of anakinra as
compared with etanercept (log-rank 0.04, figure 2).
BA switching
Switching of biological therapy was common, with 34
patients (44.2%) switching to a second, 18 (23.4%) to a
third and 4 (5.2%) to a fourth BA (figure 3). For all BA
switches (total n=56), the reasons were lack of effective-
ness in 33 patients (58.9%), loss of response in 12
(21.4%), adverse event in 7 (12.5%), and convenience
of use and patient’s choice in 2 patients each (3.6%).
Switching to a new BA was, in most cases, prescribed
after a short BA-free interval. The median treatment-free
interval was 0.8 months (range 0.0–34.2) between the
first and the second BA, 0.2 months (range 0.0–3.7)
between the second and third, and 1.9 months (range
0.5–4.8) between the third and fourth BA.
Among 51 patients on anakinra as a first BA, 21
(41%) were switched to a new BA. Out of 13 patients on
anti-TNF inhibitor as a first BA, 11 (85%) switched. Of
the 10 patients with canakinumab as first-line treatment,
2 experienced a switch (20%).
Inactive disease and drug survival after switching BA
Inactive disease at last follow-up was achieved in 37
patients with a first BA, 43 (55.8%) with a second BA, 49
(63.6%) with a third and 50 (64.9%) under a fourth BA.
Used either as first BA or after switch, the rate of
inactive disease per treatments received was 44.1% for
anakinra (59 times prescribed as a first, second, third or
fourth BA), 41.9% for canakinumab (31 times pre-
scribed) and 45% for tocilizumab (20 times prescribed).
Etanercept treatment led to a significantly lower rate of
inactive disease under treatment when compared with
anakinra and to canakinumab (p=0.03 and p=0.04,
respectively) with achievement of inactive disease only
described in 1 out of 17 courses (5.9%).
Inactive disease was more difficult to achieve when any
switch became necessary. Switching to canakinumab or
tocilizumab as second, third or fourth BA led to inactive
disease in 6 out of 19 (31.6%) and 7 out of 17 cases
(41%), respectively. No patient achieved inactive disease
Figure 1 Flow chart (CEMARA,
CEntre des MAladies RAres;
SJIA, systemic juvenile idiopathic
arthritis).
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after switching any BA to etanercept (n=5, in 2 cases
despite introduction of methotrexate), adalimumab
(n=3, in one case despite introduction of methotrexate)
or abatacept (n=2; table 2).
Patients who were switched to canakinumab (n=19) or
tocilizumab (n=17) as second-line or third-line treat-
ments, showed drug survivals at 3, 12 and 24 months of
95%, 63% and 53% for canakinumab and 94%, 82%
and 47% for tocilizumab, respectively. When anakinra
was used as a second-line or third-line treatment (n=8),
drug survival at 3, 12 and 24 months was 71%, 43% and
33%, respectively.
Clinical remission off steroids, BA withdrawal and
long-term outcome
Forty of the 50 patients who achieved inactive disease
fulfilled the criteria of clinical remission on treatment
(27 patients off steroids) at last follow-up, corresponding
to 51.9% of the study population: 23 on anakinra, 10 on
canakinumab, 5 on tocilizumab, 1 patient on etanercept
and 1 patient on abatacept.
At initiation of the first BA, 64 patients (83.1%) had
received concomitant systemic corticosteroid treatment
with a median daily dose of 0.50 mg/kg/day (range
0.1–2.0); at last follow-up, systemic corticosteroids were
given to 29 patients (37.7%) with a median daily dose of
0.21 mg/kg/day (range 0.05–0.8).
Among five patients who had never received corticos-
teroids before or during BA treatment (4 on anakinra
and 1 on canakinumab as first BA; median disease
duration 4.0 months, median age 3.6 years), two patients
under anakinra did not switch BA treatment, one
patient switched to canakinumab for convenience of
use, and one patient switched from anakinra to tocilizu-
mab for incomplete response to the first treatment. The
patient under canakinumab as first BA did not switch
treatment. All patients were in clinical remission at last
follow-up (median treatment duration 21.1 months).
BA was stopped in 12 patients after a median of
36.7 months (range 8.9–73.6), all treated with only one
BA (11 anakinra, 1 abatacept). This subpopulation did
not significantly differ in any baseline characteristics
from the group that continued treatment.
Four patients relapsed, two with systemic symptoms,
two with arthritis; inactive disease was again achieved on
non-steroidal anti-inflammatory drugs (n=2), low-dose
steroids (n=1) or resuming BA treatment (n=1).
A persisting limitation or loss of normal range of
articular motion of ≥1 joint was recorded in 45 of 77
patients (65.6%) at last follow-up. Fourteen patients had
developed short stature at last examination, with 11 chil-
dren receiving growth hormone treatment. Four patients
underwent surgical intervention for long-term complica-
tions of SJIA (hip replacement, hip arthroplasty, femoral
osteotomy, wrist arthrodesis (n=1 each)).
Safety
No case of cancer or death was recorded. Table 3 lists the
SAEs in detail. In total, 0.09 SAE/patient-year were
recorded, occurring after a median of 16 months (range
Figure 2 Kaplan-Meier estimate
of drug continuation until
discontinuation for tocilizumab,
canakinumab, anakinra and
etanercept, as a first biological
agent for adverse events,
ineffectiveness of treatment, loss
of response, convenience of use
and patient’s choice. Censoring,
defined as the time of
discontinuation or, when a patient
was still receiving the drug, the
time of the last study visit, is
shown by vertical lines.
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0–34). There were no significant differences in SAE fre-
quency between the different BA treatments. Eleven out of
total 24 SAE (46%) occurred under concomitant cortico-
steroid treatment, 1 (4%) under methotrexate, and 3
(13%) under combined corticosteroid and methotrexate
treatment. Nine of the SAE were classified as non-
infectious. Two cases of macrophage activation syn-
drome were documented. BA treatment was stopped in
both patients and another BA was started afterwards.
SAE led to temporary BA treatment withdrawal in 10
patients, with recurrence of systemic symptoms in
3. Reintroduction of the same BA resulted in dis-
appearance of the systemic features. Eight SAE led to
definitive withdrawal of the BA, two under etanercept,
one under anakinra, one SAE under canakinumab and
four under tocilizumab. Six of these eight patients were
switched to a new BA after 1 (n=2), 6 (n=2), 14 or
34 months. No SAE occurred afterwards.
Table 2 Inactive disease under treatment at last follow-up
First agent
(%)
Second agent
(%)
Third agent
(%)
Fourth agent (%)
Etanercept 1/12 (8) 0/4 (0) – 0/1 (0)
Adalimumab 0/1 (0) 0/2 (0) 0/1 (0) –
Abatacept 1/1 (100) 0/1 (0) 0/1 (0) –
Anakinra 26/51 (51) 0/7 (0) 0/1 (0) –
Canakinumab 7/10 (70) 4/14 (29) 2/5 (40) 0/2 (0)
Tocilizumab 2/2 (100) 2/6 (33) 4/11 (36) 1/1 (100)
Total inactive disease 37/77 6/34 6/19 1/4
Figure 3 Switching of biological agents (BAs), and achievement of inactive disease and clinical remission (CR). ETA,
etanercept; TCZ, tocilizumab. §The only patient on adalimumab (ADA) as first-line treatment was switched after 9.5 months to
anakinra (ANA) and steroids, then canakinumab (CAN) and steroids, but arthritis persisted. ¶The only patient on abatacept (ABA)
as first-line treatment initially achieved partial response and was in CR at last follow-up. *Six patients with ANA as a first BA and
two patients with ANA as a second BA experienced secondary introduction of methotrexate (median delay of introduction
10.5 months after start of ANA, range 6–25 months). Four patients with ANA as a first BA achieved inactive disease that
persisted at last follow-up.
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DISCUSSION
This study describes drug survival and switch of BAs in
patients with SJIA, and the achievement of inactive
disease or clinical remission on different BAs in a setting
of non-restricted access to different biological treatments
at any point of clinical course.
In the present report, BA treatment allowed most
patients to achieve inactive disease and more than half of
the patients were in clinical remission at last follow-up.
Achievement of inactive disease and clinical remission
has become a realistic goal for SJIA, with the increasing
availability of BA. Studies addressing the clinical outcome
in juvenile idiopathic arthritis that were published before
introduction of BAs reported remission rates of 15–20%
in SJIA.20 21 While treatment with TNF-α inhibitors
showed significant improvement for patients with SJIA in
terms of ACRpedi 30 or more, remission rates ranged
from 13% to 38%.4 5 22 23 The introduction of IL-1 and
IL-6 inhibitors increased the frequencies of ACRpedi 90
or inactive disease to about 60%, which is in accordance
with our findings.5 12 14 24 25
Introducing an IL-1 or IL-6 inhibitor as the first BA
appears to be the best option to increase the probabil-
ity of achieving inactive disease in most patients. Early
introduction of BAs may even prevent patients from
receiving corticosteroids, as shown in a prospective
study on 20 patients with SJIA with anakinra as first-line
treatment.6 As in our study, anakinra has been most fre-
quently used in recent years as the first BA in other
observational studies.26 Anakinra, when used as a first
BA, was associated with significantly longer drug sur-
vival as compared with etanercept. This is in
Table 3 Serious adverse events and safety of switching under BA treatment
Order of
treatment Adverse event
Duration of
treatment until
onset of AE,
months
Concomitant
medication
Severity of
event*
Stop of BA
treatment
Resolved
without
sequelae
Etanercept (17 patients; 28.5 patient-years)
1st Crohn’s disease 12 – H No No
1st Restrictive pulmonary
syndrome
19 Cs H Yes No
1st ANCA-positive
glomerulonephritis
34 Cs H Yes No
4th Varicella infection 4 Cs, MTX H Temporarily Yes
Abatacept (3 patients; 9.6 patient-years)
3rd Pyelonephritis 1 – H Temporarily Yes
Anakinra (58 patients; 127.7 patient-years)
1st Macrophage
activation syndrome
1 Cs H Yes Yes
1st Salmonella infection 34 Cs N No Yes
1st Varicella infection 37 Cs D Temporarily Yes
1st Varicella infection 20 – H Temporarily Yes
1st Mycoplasma
pneumonia
4 Cs H Temporarily Yes
1st Pneumonia 21 – H Temporarily Yes
Canakinumab (30 patients; 48.7 patient-years)
1st CMV infection 23 – H No Yes
1st Lymphadenitis 20 – H No Yes
1st Eczema 6 – D No Yes
1st Vulvitis 25 Cs D No Yes
2nd Lyme disease 32 Cs D Temporarily Yes
2nd Gastroenteritis 16 Cs, MTX H Temporarily Yes
2nd Macrophage
activation syndrome
3 Cs H Yes Yes
3rd CMV infection 5 MTX N Temporarily Yes
4th Varicella infection 20 Cs, MTX N Temporarily Yes
Tocilizumab (20 patients; 27.9 patient-years)
2nd Crohn’s disease 13 Cs H Yes No
3rd Toxidermia 5 Cs H Yes Yes
4th Cutaneous vasculitis 14 – H Yes No
4th Infusion reaction 0 Cs H Yes Yes
*Severity of event: H=hospitalisation, D=temporary disruption of otherwise executable life functions, N=not clearly specified severity in medical
records.
AE, adverse event; ANCA, anti-neutrophil cytoplasmic antibodies; BA, biological agent; CMV, cytomegalovirus; Cs, corticosteroids; MTX,
methotrexate.
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accordance with the study of Tynjälä et al,24 who
showed that a significant predictor of discontinuation
of a first TNF-blocker therapy was SJIA compared with
non-systemic JIA. Otten et al described significantly
longer drug survival of anakinra compared with TNF
blockers in SJIA when used as second BA after failure
of etanercept. By contrast, drug survival of anakinra as
a second/third BA was not different from etanercept as
first BA.27 In our study, the response rate to anakinra
was strikingly different between biological-naive and
biological-experienced patients. Drug survival of ana-
kinra as second/third BA was only 43% after 12 months
of treatment, as compared with 63% on canakinumab
and 82% on tocilizumab.
Switching to a second, third or fourth BA was
common, and increased the frequency of inactive
disease at last follow-up in two-thirds of the patients.
However, in non-BA-naive patients, clinical remission was
only achieved on canakinumab or tocilizumab. Also, in
our study, the chance of achieving clinical remission
after failing a first BA appears much lower.
Other studies addressing the effectiveness of switching
to a second or third BA are scarce. In the study pub-
lished by Otten et al,27 all patients with SJIA received eta-
nercept as first BA. Switching was frequent, with 24
patients (47%) switched to a second BA (14 to anakinra,
8 on a second TNF blocker, 2 to a not further specified
trial drug) and 13 patients switched to a third BA. The
frequency of inactive disease was not reported. In
accordance with our study, reasons for switch or discon-
tinuation of TNF blockers were most frequently lack of
effectiveness or intolerance.
In patients achieving clinical remission, withdrawing or
tapering the dose of steroids was achieved in most cases. A
recent study evaluating the long-term outcome of tocilizu-
mab treatment in SJIA reported that a third of the patients
were able to discontinue steroids.28 By contrast, only a few
patients were able to withdraw BA treatment and maintain
long-lasting clinical remission. The question of optimal
tapering and eventual withdrawal of a BA in the face of
inactive disease is still unanswered. De Benedetti et al
reported results from an alternative dosing regimen for
tocilizumab in patients with SJIA with inactive disease
status and a 3-week interval followed by a 4-week interval.
Twenty-six of a total 39 patients remained in clinically
inactive disease during tapering, and 9 patients discontin-
ued tocilizumab.29 In our centre, 12 out of 77 patients
(15%) discontinued BA treatment for clinical remission,
with 11 being treated with anakinra as the only BA.
The frequency of SAE in our study is consistent with
other publications.14 30 31 No new SAE signals emerged
during more than 240 patient-years under different BAs.
For anakinra, canakinumab and abatacept, mainly infec-
tions were reported, whereas etanercept and tocilizumab
were more frequently associated with non-infectious
events in our study. Eight of nine reported non-
infectious events led to BA withdrawal. Switching BA did
not lead to further SAE at last follow-up.
Our study has several limitations. First, even when col-
lected from a register, our data are of retrospective
nature, and not all data were available at certain time
points. Second, our results are mainly descriptive, as the
small subsets of treatment groups without adjustments
require caution when interpreting any direct compari-
sons. Third, CHAQ as proposed by Wallace et al,18 or
other parameters of patient functional status were not
systematically included. Future studies would potentially
profit from the validated Juvenile Arthritis Disease
Activity Score, as proposed by Consolaro et al.32 Fourth,
follow-up duration was less than 1 year in some patients
who switched BA, limiting long-term outcome data.
Fifth, our population was followed in a tertiary centre,
with a probable recruitment bias towards more severe
cases.
In conclusion, IL-1 inhibitors were associated with a
higher proportion of inactive disease than TNF inhibi-
tors when used as first BA. Switching was an appropriate
therapeutic approach, increasing the frequency of
inactive disease and clinical remission when patients
non-naïve from BA received canakinumab or tocilizu-
mab. Complete remission was eventually achieved in
more than half the patients. Long-term follow-up of
patients with JIA and particularly patients with SJIA on
BA will be provided by collaborative efforts such as the
PharmaChild project.
Author affiliations
1Department of Paediatric Immunology, Hematology and Rheumatology and
Institut IMAGINE, Hôpital Necker-Enfants Malades, Assistance Publique
Hôpitaux de Paris, Paris, France
2Department of Pediatric Rheumatology, University of Basel, University
Children’s Hospital, Basel, Switzerland
3Clocheville Hospital, Tours, France
4Department of Pediatrics, Hôpital Robert Debré, Assistance Publique
Hôpitaux de Paris, Paris, France
5Department of Microbiology and Immunology, Pediatric Immunology and
Pediatric Rheumatology, KU Leuven-University of Leuven, University Hospitals
Leuven, Leuven, Belgium
6Université Paris-Descartes, Paris, France
Acknowledgements The authors thank Caroline Elie, Clinical Research Unit,
Hôpital Necker-Enfants Malades, Paris, France, for statistical support, and
Solimda Sotou-Bere, Centre of Clinical Investigations, Hôpital Necker-Enfants
Malades, Paris, France, for technical assistance.
Contributors AW, BB-M and PQ were involved in study conception, design
and data analysis. FU, IM and CW made contributions to data acquisition and
analysis. RM made contributions to data acquisition. AW and PQ drafted the
manuscript. All authors contributed in editing and reviewing the manuscript,
and approved the final version of the paper.
Funding This work was partially supported by a grant from Novartis SA,
France.
Competing interests PQ, BB-M and RM are investigators of clinical trials with
etanercept, adalimumab, abatacept, tocilizumab and canakinumab. PQ
received, outside the submitted work, research grants from Abbvie, BMS,
Novartis, Pfizer and Roche, and speaker bureau or consultant for Abbvie,
BMS, Novartis, Pfizer and Roche.
Ethics approval French National Committee on Informatics and Liberty
(CNIL).
Provenance and peer review Not commissioned; externally peer reviewed.
8 Woerner A, et al. RMD Open 2015;1:e000036. doi:10.1136/rmdopen-2014-000036
RMD Open
group.bmj.com on August 25, 2015 - Published by http://rmdopen.bmj.com/Downloaded from 
Data sharing statement No additional data are available.
Open Access This is an Open Access article distributed in accordance with
the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license,
which permits others to distribute, remix, adapt, build upon this work non-
commercially, and license their derivative works on different terms, provided
the original work is properly cited and the use is non-commercial. See: http://
creativecommons.org/licenses/by-nc/4.0/
REFERENCES
1. Petty RE, Southwood TR, Manners P, et al. International League of
Associations for Rheumatology classification of juvenile idiopathic
arthritis: second revision, Edmonton, 2001. J Rheumatol
2004;31:390–2.
2. Pascual V, Allantaz F, Arce E, et al. Role of interleukin-1 (IL-1) in the
pathogenesis of systemic onset juvenile idiopathic arthritis and
clinical response to IL-1 blockade. J Exp Med 2005;201:1479–86.
3. Mellins ED, Macaubas C, Grom AA. Pathogenesis of systemic
juvenile idiopathic arthritis: some answers, more questions. Nat Rev
Rheumatol 2011;7:416–26.
4. Quartier P, Taupin P, Bourdeaut F, et al. Efficacy of etanercept for
the treatment of juvenile idiopathic arthritis according to the onset
type. Arthritis Rheum 2003;48:1093–101.
5. Horneff G, Schmeling H, Biedermann T, et al. The German
etanercept registry for treatment of juvenile idiopathic arthritis. Ann
Rheum Dis 2004;63:1638–44.
6. Vastert SJ, de Jager W, Noordman BJ, et al. Effectiveness of
first-line treatment with recombinant interleukin-1 receptor antagonist
in steroid-naive patients with new-onset systemic juvenile idiopathic
arthritis: results of a prospective cohort study. Arthritis Rheum
2014;66:1034–43.
7. Lequerre T, Quartier P, Rosellini D, et al. Interleukin-1 receptor
antagonist (anakinra) treatment in patients with systemic-onset
juvenile idiopathic arthritis or adult onset Still disease: preliminary
experience in France. Ann Rheum Dis 2008;67:302–8.
8. Nigrovic PA, Mannion M, Prince FH, et al. Anakinra as first-line
disease-modifying therapy in systemic juvenile idiopathic arthritis:
report of forty-six patients from an international multicenter series.
Arthritis Rheum 2011;63:545–55.
9. Gattorno M, Piccini A, Lasiglie D, et al. The pattern of response to
anti-interleukin-1 treatment distinguishes two subsets of patients with
systemic-onset juvenile idiopathic arthritis. Arthritis Rheum
2008;58:1505–15.
10. Zeft A, Hollister R, LaFleur B, et al. Anakinra for systemic juvenile
arthritis: the Rocky Mountain experience. J Clin Rheumatol
2009;15:161–4.
11. Quartier P, Allantaz F, Cimaz R, et al. A multicentre, randomised,
double-blind, placebo-controlled trial with the interleukin-1
receptor antagonist anakinra in patients with systemic-onset juvenile
idiopathic arthritis (ANAJIS trial). Ann Rheum Dis 2011;70:747–54.
12. Ruperto N, Brunner HI, Quartier P, et al. Two randomized trials of
canakinumab in systemic juvenile idiopathic arthritis. New Engl J
Med 2012;367:2396–406.
13. De Benedetti F, Brunner HI, Ruperto N, et al. Randomized trial of
tocilizumab in systemic juvenile idiopathic arthritis. New Engl J Med
2012;367:2385–95.
14. Lovell DJ, Giannini EH, Reiff AO, et al. Long-term safety and efficacy
of rilonacept in patients with systemic juvenile idiopathic arthritis.
Arthritis Rheum 2013;65:2486–96.
15. Beukelman T, Patkar NM, Saag KG, et al. 2011American College of
Rheumatology recommendations for the treatment of juvenile
idiopathic arthritis: initiation and safety monitoring of therapeutic
agents for the treatment of arthritis and systemic features. Arthritis
Care Res 2011;63:465–82.
16. Ringold S, Weiss PF, Beukelman T, et al. 2013 update of the 2011
American College of Rheumatology recommendations for the
treatment of juvenile idiopathic arthritis: recommendations for the
medical therapy of children with systemic juvenile idiopathic arthritis
and tuberculosis screening among children receiving biologic
medications. Arthritis Care Res 2013;65:1551–63.
17. Landais P, Messiaen C, Rath A, et al. CEMARA an information
system for rare diseases. Stud Health Technol Inform 2010;160(Pt
1):481–5.
18. Wallace CA, Giannini EH, Huang B, et al. American College of
Rheumatology provisional criteria for defining clinical inactive
disease in select categories of juvenile idiopathic arthritis. Arthritis
Care Res 2011;63:929–36.
19. Wallace CA, Huang B, Bandeira M, et al. Patterns of clinical
remission in select categories of juvenile idiopathic arthritis. Arthritis
Rheum 2005;52:3554–62.
20. Lomater C, Gerloni V, Gattinara M, et al. Systemic onset juvenile
idiopathic arthritis: a retrospective study of 80 consecutive patients
followed for 10 years. J Rheumatol 2000;27:491–6.
21. Oen K. Long-term outcomes and predictors of outcomes for patients
with juvenile idiopathic arthritis. Best Pract Res Clin Rheumatol
2002;16:347–60.
22. Kimura Y, Pinho P, Walco G, et al. Etanercept treatment in patients
with refractory systemic onset juvenile rheumatoid arthritis.
J Rheumatol 2005;32:935–42.
23. Prince FH, Twilt M, ten Cate R, et al. Long-term follow-up on
effectiveness and safety of etanercept in juvenile idiopathic
arthritis: the Dutch national register. Ann Rheum Dis
2009;68:635–41.
24. Tynjälä P, Vahasalo P, Honkanen V, et al. Drug survival of the first
and second course of anti-tumour necrosis factor agents in juvenile
idiopathic arthritis. Ann Rheum Dis 2009;68:552–7.
25. Singh-Grewal D, Schneider R, Bayer N, et al. Predictors of disease
course and remission in systemic juvenile idiopathic arthritis:
significance of early clinical and laboratory features. Arthritis Rheum
2006;54:1595–601.
26. Otten MH, Anink J, Prince FHM, et al. Trends in prescription of
biological agents and outcomes of juvenile idiopathic arthritis: results
of the Dutch national Arthritis and Biologics in Children Register.
Ann Rheum Dis 2014 Published Online First: 18 Mar 2014.
doi: 10.1136/annrheumdis-2013-204641
27. Otten MH, Prince FH, Anink J, et al. Effectiveness and safety of a
second and third biological agent after failing etanercept in juvenile
idiopathic arthritis: results from the Dutch National ABC Register.
Ann Rheum Dis 2013;72:721–7.
28. Yokota S, Imagawa T, Mori M, et al. Longterm safety and
effectiveness of the anti-interleukin 6 receptor monoclonal antibody
tocilizumab in patients with systemic juvenile idiopathic arthritis in
Japan. J Rheumatol 2014;41:759–67.
29. De Benedetti F, Ruperto N, Brunner H, et al. Tapering and
withdrawal of tocilizumab in patients with systemic juvenile idiopathic
arthritis in inactive disease: results from an alternative dosing
regimen in the TENDER study. Arthritis Rheum 2014;66(Suppl 11):
S8–9.
30. Horneff G, De Bock F, Foeldvari I, et al. Safety and efficacy of
combination of etanercept and methotrexate compared to treatment
with etanercept only in patients with juvenile idiopathic arthritis ( JIA):
preliminary data from the German JIA Registry. Ann Rheum Dis
2009;68:519–25.
31. Lovell DJ, Reiff A, Ilowite NT, et al. Safety and efficacy of up
to eight years of continuous etanercept therapy in patients
with juvenile rheumatoid arthritis. Arthritis Rheum
2008;58:1496–504.
32. Consolaro A, Ruperto N, Bazso A, et al. Development and validation
of a composite disease activity score for juvenile idiopathic arthritis.
Arthritis Rheum 2009;61:658–66.
Woerner A, et al. RMD Open 2015;1:e000036. doi:10.1136/rmdopen-2014-000036 9
Paediatric rheumatology
group.bmj.com on August 25, 2015 - Published by http://rmdopen.bmj.com/Downloaded from 
second or third biological agent
disease or clinical remission on a first,
idiopathic arthritis: achievement of inactive 
Biological treatment in systemic juvenile
and P Quartier
A Woerner, F Uettwiller, I Melki, R Mouy, C Wouters, B Bader-Meunier
doi: 10.1136/rmdopen-2014-000036
2015 1: RMD Open 
http://rmdopen.bmj.com/content/1/1/e000036
Updated information and services can be found at: 
These include:
References
#BIBLhttp://rmdopen.bmj.com/content/1/1/e000036
This article cites 31 articles, 11 of which you can access for free at: 
Open Access
http://creativecommons.org/licenses/by-nc/4.0/non-commercial. See: 
provided the original work is properly cited and the use is
non-commercially, and license their derivative works on different terms, 
permits others to distribute, remix, adapt, build upon this work
Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
This is an Open Access article distributed in accordance with the Creative
service
Email alerting
box at the top right corner of the online article. 
Receive free email alerts when new articles cite this article. Sign up in the
Notes
http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
http://journals.bmj.com/cgi/reprintform
To order reprints go to:
http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
group.bmj.com on August 25, 2015 - Published by http://rmdopen.bmj.com/Downloaded from 
